[Immune response to Epstein-Barr virus in patients with otorhinolaryngologic neoplasms of various morphology and invasiveness].

Both nasopharyngeal and tumors and epithelial cancer of topographically different sites of the mouth, laryngopharynx are shown to be associated in many cases with high immunity to virus Epstein-Barr (VEB) antigens. VEB-associated antibody quantitation in patients with laryngeal, laryngopharyngeal, oral and lingual cancer revealed that the malignant process dissemination and the tumor differentiation are related to immune response to VEB antigens: the more advanced is cancer and the poorer is its differentiation, the more pronounced is the immune response.

[The determination of the level of antibodies to Epstein-Barr virus antigens in organizing groups at high risk for lung cancer disease].

Titers of antibodies against Epstein-Barr virus (EBV) antigen were measured in 450 subjects aged 40 years and older. The group included patients with lung cancer, cases of non-specific chronic lung pathology and healthy subjects (150 persons in each subset). A significant increase in the level of antibodies to capsid EBV antigen was established in patients with lung cancer and chronic non-specific lung pathology as compared to healthy controls.

[The level of antibodies to Epstein-Barr virus antigens in the blood serum of the inhabitants of southern Siberia and the Far East].

Antibodies to Epstein-Barr virus have been detected in sera from 1538 healthy adult persons living in the south of Siberia and Far East. It has been shown that the virus infectivity varied from 77% in Russians of the Yakutsk ASSR to 100% in Orochi and Russians residing in the territory of the Gorno-Altai Autonomous Province. Antibody levels to the Epstein-Barr virus for inhabitants of the south regions were higher than those for inhabitants of the north regions.

[Diagnostic significance of determining antibodies to antigens of the Epstein-Barr virus in infectious mononucleosis].

Infectious mononucleosis may be differentiated from clinically similar diseases by the detection of classes M and A antibodies to Epstein-Barr virus capsid antigen. The authors emphasize the high specificity of this test vs. the detection of the Paul-Bunnell-Davidson heterophilic antibodies.